MSB11022 in Moderate to Severe Rheumatoid Arthritis
Status:
Completed
Trial end date:
2018-08-27
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the efficacy, safety and immunogenicity of MSB11022
and Humira® in adult participants with rheumatoid arthritis (RA).